Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DABI-ADP-2: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation.

Next Previous
Trial Profile

DABI-ADP-2: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Phenprocoumon
  • Indications Embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms Dabi-ADP-2

Most Recent Events

  • 01 Jul 2013 Planned End Date changed from 1 Mar 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
  • 24 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
  • 16 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top